Safety and immunogenicity of the live-attenuated hRVFV-4s vaccine against Rift Valley fever in healthy adults: a dose-escalation, placebo-controlled, first-in-human, phase 1 randomised clinical trial

Isabel Leroux‐Roels, Chittappen Kandiyil Prajeeth, Amare Aregay, Niranjana Nair, Guus F. Rimmelzwaan, Albert Osterhaus, Simone Kardinahl, S Pelz, S. P. Bauer, Valentino D’Onofrio, Azhar Alhatemi, Bart Jacobs, Fien De Boever, Sharon Porrez, Gwenn Waerlop, Carine Punt, Bart Hendriks, Ellemieke von Mauw, Sandra van de Water, José Harders-Westerveen, Barry Rockx, Lucien van Keulen, Jeroen Kortekaas, Geert Leroux‐Roels, Paul J. Wichgers Schreur